Cardiovascular effects of Danshen

International Journal of Cardiology

Volumn 121, Issue 1, 2007, Pages 9-22

  Cheng, Tsung O ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Arrhythmias; Chromatography; Coronary artery disease; Danshen; Drug interactions; Ginseng; Hypertension; Salvia miltiorrhizae binge; Stroke; Traditional Chinese medicine

Indexed keywords

ALCOHOL; AMINOGLYCOSIDE; DIAZEPAM; DIGOXIN; GINSENG EXTRACT; SALICYLIC ACID; SALVIA MILTIORRHIZA EXTRACT; WARFARIN;

ABDOMINAL DISCOMFORT; ALCOHOLISM; ANGINA PECTORIS; APPETITE; CARDIOGENIC SHOCK; CARDIOTOXICITY; CARDIOVASCULAR EFFECT; CONVULSION; CORONARY ARTERY DISEASE; CORONARY ARTERY SPASM; DIZZINESS; DROWSINESS; DRUG ALCOHOL INTERACTION; DRUG HYPERSENSITIVITY; DRUG STRUCTURE; DYSTONIA; EXTRACORPOREAL CIRCULATION; GINSENG; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEMORRHAGIC FEVER; HERB DRUG INTERACTION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOTENSION; INTERNATIONAL NORMALIZED RATIO; KIDNEY DISEASE; MENTAL HEALTH; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; REVIEW; SALVIA MILTIORRHIZA; SIDE EFFECT; STROKE; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULITIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DRUGS, CHINESE HERBAL; HERB-DRUG INTERACTIONS; HUMANS; HYPERLIPIDEMIAS; KIDNEY DISEASES; MYOCARDIAL REPERFUSION INJURY; PANAX; PERIPHERAL VASCULAR DISEASES; SALVIA MILTIORRHIZA;

EID: 34548079309     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.01.004     Document Type: Review

References (148)

1. Cheng T.O. Danshen: a versatile Chinese herbal drug for the treatment of coronary heart disease. Int J Cardiol 113 (2006) 437-438
2. Zhou L., Zuo Z., and Chow M.S.S. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol 45 (2005) 1345-1359
3. Guo Z.X., Jia W., Gao W.Y., Xu Z.H., Zhao L.B., and Xiao P.G. Clinical investigation of composite Danshen Dripping Pill for the treatment of angina pectoris. Zhongguo Tianran Yaowu vol. 1 (2003) 124-128
4. Cheng T.O. Warfarin Danshen interaction. Ann Thorac Surg 67 (1999) 894
5. Cheng TO. Danshen: a popular Chinese cardiac herbal drug. J Am Coll Cardiol 47 (2006) 1498
6. Cheng T.O. Danshen: what every cardiologist should know about this Chinese herbal drug. Int J Cardiol 110 (2006) 411-412
7. Lam F.F.Y., Yeung J.H.K., Cheung J.H.Y., and Or P.M.Y. Pharmacological evidence for calcium channel inhibition by Danshen (Salvia miltiorrhiza) on rat isolated femoral artery. J Cardiovasc Pharmacol 47 (2006) 139-145
8. Cheng T.O. The international textbook of cardiology (1987), Pergamon Press, New York 1067-1071
9. Cooperative group for Study of Salvia miltiorrhizae. Clinical observation of therapeutic effect of Salvia miltiorrhizae in patients with coronary heart disease. Chin J Cardiovasc Dis 2 (1974) 143-150
10. Shanghai First Medical College, Physiological Teaching Research Department, Pathological Teaching Research Department, et al. A preliminary investigation of Salvia miltiorrhizae intravenous infusion in patients with coronary heart disease. Chin J Intern Med 2 (1977) 203-206
11. Kim C.B., and Braunwald E. Potential benefits of late reperfusion of infarcted myocardium. The open artery hypothesis. Circulation 88 (1993) 2426-2436
12. Braunwald E. The open-artery theory is alive and well - again. N Engl J Med 329 (1993) 1650-1652
13. Shanghai Cooperative Group for Study of Tanshinone IIA. Therapeutic effect of sodium tanshinone IIA sulfonate intravenous infusion on 108 cases of coronary heart disease. J Chin Herbal Inf 1 (1978) 37-40
14. Shanghai Cooperative Group for the Study of Tanshinone IIA. Therapeutic effect of sodium tanshinone IIA sulfonate in patients with coronary heart disease: a double blind study. J Tradit Chin Med 4 (1984) 20-24
15. Shanghai 9th Pharmaceutic Factory. An investigation of Salvia miltiorrhizae and its infusion. Med Ind 1 (1973) 14-17
16. Jin H.M. Clinical application of Salvia miltiorrhizae and the investigation of its mechanism for activating the blood circulation to eliminate blood stasis. Nat Med J China 58 (1978) 180-183
17. Cardiovascular Department, Second Hospital, Chekiang Medical University. Clinical and laboratory investigation of coronary heart disease. Compilation of Data of Research on Prevention and Treatment of Cardiovascular Disease by Integrating Traditional Medicine and Western Medicine vol. 5 (1978) 50
18. Yu G.R., Tang X.M., Zheng D.S., Huang M.X., and Han Y.S. Change of ischemic myocardium and ultrastructure in mice after Salvia miltiorrhizae infusion. Chin. J. Integr. Tradit. West. Med. 1 (1981) 30-31
19. Zhu H.S., Jiang T.F., Wang Y.S., Feng Z.R., Fan Q.R., and Lu R.X. An investigation of effect of Salvia miltiorrhizae on the protection of myocardium during ischemic cardiac arrest. Acta Acad Med Secondae Shanghai 3 (1984) 177-179
20. Patmore L., and Whiting R.L. Calcium entry blocking properties of tanshinone II-A sulphonate, an active principal of the antianginal extract Dan Shen. Br J Pharmacol 75 (1982) 149P
21. Sun J., Huang S.H., Tan B.K.H., et al. Effects of purified herbal extract of Salvia miltiorrhiza on ischemic rat myocardium after acute myocardial infarction. Life Sci 76 (2005) 2849-2860
22. Chang P.N., Mao J.C., Huang S.H., et al. Analysis of cardioprotective effects using purified Salvia miltiorrhiza extract on isolated rat hearts. J Pharmacol Sci 101 (2006) 245-249
23. Li C.Z., Lin J.B., Yang S.C., Zhao F.D., and Zhang J.C. Effect of Salvia miltiorrhizae on the release of vasoconstrictive substance of platelets. Chin. J. Integr. Tradit. West. Med. 4 (1984) 565
24. Zhu X.X., Wang Z.Q., Chen S.H., Jin W.M., Yan Y.Z., and Zhu Z.R. Effect of Danshen and persantin on the alteration of platelet aggregation and microcirculation in diabetics. Chin J Intern Med 24 (1985) 197-199
25. Zhao F.Q., Zheng N.X., Sato H., Adachi I., and Horikoshi I. Pharmacokinetics of a Chinese traditional medicine, danshensu (3,4-dihydroxyphenyllactic acid), in rabbits using high-performance liquid chromatography. Biol Pharm Bull 20 (1997) 285-287
26. Guo Y.X., Zhang D.J., Wang H., Xiu Z.L., Wang L.X., and Xiao H.B. Hydrolytic kinetics of lithospermic acid B extracted from roots of Salvia miltiorrhiza. J Pharm Biomed Anal 43 (2007) 435-439
27. Kim H.H., Kim J., Ji H.Y., et al. Pharmacokinetics of lithospermic acid B isolated from Salvia miltiorrhiza in rats. J Toxicol Environ Health A 68 (2005) 2239-2247
28. Zhang Y., Akao T., Nakamura N., et al. Extremely low bioavailability of magnesium lithospermate B, an active component from Salvia miltiorrhiza, in rat. Planta Med 70 (2004) 138-142
29. Ye G., Wang C.S., Li Y.Y., Ren H., and Guo D.A. Simultaneous determination and pharmacokinetic studies on (3,4-dihydroxyphenyl)-lactic acid and protocatechuic aldehyde in rat serum after oral administration of Radix Salviae miltiorrhizae extract. J Chromatogr Sci 41 (2003) 327-330
30. Ling S., Dai A., Guo Z., Yan X., and Komesaroff P.A. Effects of a Chinese herbal preparation on vascular cells in culture: mechanisms of cardiovascular protection. Clin Exp Pharmacol Physiol 32 (2005) 571-578
31. Ji X.Y., Tan B.K., and Zhu Y.Z. Salvia miltiorrhiza and ischemic diseases. Acta Pharmacol Sin 21 (2000) 1089-1094
32. Wang L., Xiong Z.Y., and Wang G. Systematic assessment on randomized controlled trials for treatment of stable angina pectoris by compound salvia pellet. Zhongguo Zhong Xi Yi Jie He Za Zhi 24 (2004) 500-504
33. Zhang Q., Liu A.D., and Huang Y.S. Clinical non-inferiority trial on treatment of coronary heart disease angina pectoris of Xin-blood stasis syndrome type with lyophilized salvia salt of lithospermic acid powder for injection. Chin J Integr Med 12 (2006) 12-18
34. Wang G., Wang L., Xiong Z.Y., Mao B., and Li T.Q. Compound salvia pellet, a traditional Chinese medicine, for the treatment of chronic stable angina pectoris compared with nitrates: a meta-analysis. Med Sci Monit 12 (2006) SR1-SR7
35. Wu H.L., Wang X., Li X.M., Luo W.J., and Deng T.T. Trial study on DENG Tie-tao's coronary heart disease capsules in improving patients' quality of life. Chin J Integr Med 11 3 (2005) 173-178
36. Prinzmetal M., Kennamer R., Merliss R., Wada T., and Bor N. Angina pectoris: I. A variant form of angina pectoris: preliminary report. Am J Med 27 (1959) 375-388
37. Cheng T.O., Bashour T., Singh B.K., and Kelser G.A. Myocardial infarction in the absence of coronary arteriosclerosis: result of coronary spasm(?). Am J Cardiol 30 (1972) 680-682
38. Cheng T.O. Coronary artery spasm - 1984. Chest 86 (1984) 918-926
39. Cheng T.O. Coronary artery spasm. Chin J Intern Med 23 (1984) 179-184
40. Cheng T.O., Bashour T., Kelser G.A., Weiss L., and Bacos J. Variant angina of Prinzmetal with normal coronary arteriogram. A variant of the variant. Circulation 47 (1973) 476-485
41. Chen K.J. Certain progress in the treatment of coronary heart disease with traditional medicinal plants in China. Am J Chin Med 9 (1981) 193-196
42. Liu Q., and Lu Z. Effect of Salvia miltirrhiza on coronary collateral circulation in dogs with experimental acute myocardial infarction. J Tongji Med Univ 19 (1999) 40-1,69
43. Ji X.Y., Tan B.K.H., Zhu Y.C., Linz W., and Zhu Y.Z. Comparison of cardioprotective effects using ramipril and DanShen for the treatment of acute myocardial infarction in rats. Life Sci 73 (2003) 1413-1426
44. Chen J.X., Wang S.R., Zhao M.J., Lu X.Y., Zhang Z., and Qin Y. Effect of different drug dosage to activate blood circulation and to nourish qi on cardiac function and structure of congestive heart failure rats after acute myocardial infarction. Zhongguo Zhong Yao Za Zhi 28 (2003) 446-449
45. Geng Q.X., Zhu X.L., and Zhang X.H. Effect of combined therapy of shenmai and compound Danshen injection on myocardial reperfusion injury after percutaneous coronary interventions in patients with acute myocardial infarction. Zhongguo Zhong Xi Yi Jie He Za Zhi 24 (2004) 496-499
46. Li X., Du J.R., Zhang R., Zhang L.F., and Qian Z.M. The experimental study of the effect of tanshinone on artery restenosis in mouse. Zhongguo Zhong Yao Za Zhi 29 (2004) 255-258
47. Liu Y.L., and Liu G.T. Inhibition of human low-density lipoprotein oxidation by salvianolic acid-A. Yao Xue Xue Bao 37 2 (2002) 81-85
48. O.K., Lynn E.G., Vazhappilly R., Au-Yeung K.K., Zhu D.Y., and Siow Y.L. Magnesium tanshinoate B (MTB) inhibits low density lipoprotein oxidation. Life Sci 68 (2001) 903-912
49. Yang H., Han L., Sheng T., He Q., and Liang J. Effects of replenishing qi, promoting blood circulation and resolving phlegm on vascular endothelial function and blood coagulation system in senile patients with hyperlipidemia. J Tradit Chin Med 26 2 (2006) 120-124
50. Li S., and Wan L. Experimental study on the preventive mechanism of Salviae miltiorrhizae against atherosclerosis in rabbits models. J Huazhong Univ Sci Technolog Med Sci 24 (2004) 233-235
51. Cheng T.O. Hyperhomocysteinaemia and the heart. Q J Med 89 (1996) 877-878
52. Cheng T.O. Homocysteinaemia and coronary atherosclerosis. Heart 77 (1997) 390-391
53. Cheng T.O. Hyperhomocysteinemia is a risk factor for coronary artery disease even in the presence of elevated high-density lipoprotein cholesterol. Am J Cardiol 80 (1997) 683
54. Cheng T.O. Hyperhomocysteinaemia. Postgrad Med J 73 (1997) 606-607
55. Cheng T.O. Homocysteine, B vitamins, and atherosclerosis. Circulation 99 (1999) 459
56. Cheng T.O. Homocysteine and coronary artery disease. Atherosclerosis 145 (1999) 419
57. Glueck C.J., Shaw P., Lang J.E., Tracy T., Sieve-Smith L., and Wang Y. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol 75 (1995) 132-136
58. Gravina-Taddei C.F., Batlouni M., Sartesch C., et al. Hyperhomocysteinemia as a risk factor for coronary atherosclerotic diseases in the elderly. Arq Bras Cardiol 85 (2005) 166-173
59. Chan K., Chui S.H., Wong D.Y., Ha W.Y., Chan C.L., and Wong R.N. Protective effects of danshensu from the aqueous extract of Salvia miltiorrhiza (Danshen) against homocysteine-induced endothelial dysfunction. Life Sci 75 (2004) 3157-3171
60. Kang D.G., Oh H., Chung H.T., and Lee H.S. Inhibition of angiotensin converting enzyme by lithospermic acid B isolated from Radix Salviae miltiorrhiza Bunge. Phytother Res 17 (2003) 917-920
61. Kang D.G., Yun Y.G., Ryoo J.H., and Lee H.S. Anti-hypertensive effect of water extract of Danshen on renovascular hypertension through inhibition of the renin angiotensin system. Am J Chin Med 30 (2002) 87-93
62. Gao X.P., Xu D.Y., Deng Y.L., and Zhang Y. Screening of angiotensin converting enzyme inhibitors from Salvia miltirrhizae. Zhongguo Zhong Yao Za Zhi 29 (2004) 359-362
63. Jiang R.W., Lau K.M., Hon P.M., Mak T.C., Woo K.S., and Fung K.P. Chemistry and biological activities of caffeic acid derivatives from Salvia miltiorrhiza. Curr Med Chem 12 (2005) 237-246
64. Watzke A., O'Malley S.J., Bergman R.G., and Ellman J.A. Reassignment of the configuration of salvianolic acid B and establishment of its identity with lithospermic acid B. J Nat Prod 69 (2006) 1231-1233
65. Cheng W.L., Qian Z.F., and Su J. Effect of huoxue tablet on the rheology of erythrocyte in primary hypertension. Zhongguo Zhong Xi Yi Jie He Za Zhi 17 (1997) 718-720
66. Yu G.R., Zheng S.H., Xie X.L., et al. Effect of Salvia miltiorrhizae on dog's mesenteric microcirculatory blood flow measured by Doppler's effect of laser light. Chin J Integr Tradit West Med 4 (1984) 546-547
67. Wang X.F., and Zhao M.Q. Ligustrazine and Salvia miltiorrhiza injection solution in complementary therapy of pregnancy-induced hypertension: clinical analysis of 60 cases. Di Yi Jun Yi Da Xue Xue Bao 23 (2003) 969-971
68. Han S., Zheng Z., and Ren D. Effect of Salvia miltiorrhiza on left ventricular hypertrophy and cardiac aldosterone in spontaneously hypertensive rats. J Huazhong Univ Sci Technolog Med Sci 22 (2002) 302-304
69. Ouyang X.S., Takahashi K., Komatsu K., et al. Protective effect of Salvia miltiorrhiza on angiotensin II-induced hypertrophic responses in neonatal rat cardiac cells. Jpn J Pharmacol 87 (2002) 289-296
70. Haber H.L., Powers E.R., Gimple L.W., et al. Intracoronary angiotensin-converting inhibition improves diastolic function in patients with hypertensive left ventricular hypertrophy. Circulation 89 (1994) 2616-2625
71. Qiu Z.X., Ma H.J., and Wang D.F. Observation on effect of compound Danshen droplet-pill combined with trimetazidine in treating senile unstable angina pectoris. Zhongguo Zhong Xi Yi Jie He Za Zhi 25 (2005) 787-789
72. Han Y., Wang Z.K., Wang Z.D., Wu Y., and Chen T.Z. Observation on therapeutic effect of compound salvia drop-pill in treating vasovagal syncope. Zhongguo Zhong Xi Yi Jie He Za Zhi 24 (2004) 452-454
73. Fish J.M., Welchons D.R., Kim Y.S., Lee S.H., Ho W.K., and Antzelevitch C. Dimethyl lithospermate B, an extract of Danshen, suppresses arrhythmogenesis associated with the Brugada syndrome. Circulation 113 (2006) 1393-1400
74. Antzelevitch C., Brugada P., Brugada J., and Brugada R. The Brugada syndrome: from bench to bedside (2005), Blackwell Futura, Oxford, UK
75. Antzelevitch C., and Fish J.M. Therapy for the Brugada syndrome. In: Kass R., and Clancy C.E. (Eds). Handbook of experimental pharmacology (2006), Springer-Verlag, New York 305-330
76. Antzevitch C., Brugada P., Borggrefe M., et al. Brugada syndrome: report of the Second Consensus Conference, endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 111 (2005) 659-670
77. Dong J.C., and Xu L.N. Beneficial effects of acetylsalvianolic acid A on focal cerebral ischemic rats subjected to middle cerebral artery thrombosis. Yao Xue Xue Bao 31 (1996) 6-9
78. Lam B.Y., Lo A.C., Sun X., Luo H.W., Chung S.K., and Sucher N.J. Neuroprotective effects of tanshinones in transient focal cerebral ischemia in mice. Phytomedicine 10 (2003) 286-291
79. Min L.Q., Dang L.Y., and Ma W.Y. Clinical study on effect and therapeutic mechanism of composite Salvia injection on acute cerebral infarction. Zhongguo Zhong Xi Yi Jie He Za Zhi 22 (2002) 353-355
80. Zhang R.J., You C., Cai B.W., Wan Y., He M., and Li H. Effect of compound Salvia injection on blood coagulation in patients with traumatic cerebral infarction. Zhongguo Zhong Xi Yi Jie He Za Zhi 24 (2004) 882-884
81. Wu B., Liu M., and Zhang S. Dan Shen agents for acute ischaemic stroke. Cochrane Database Syst Rev 4 (Oct 18 2004) CD004295
82. Sze F.K., Yeung F.F., Wong E., and Lau J. Does Danshen improve disability after acute ischaemic stroke?. Acta Neurol Scand 111 (2005) 118-125
83. Lam F.F.Y., Yeung J.H.K., and Cheung J.H.Y. Mechanisms of the dilator action of Danshen (Salvia miltiorrhiza) on rat isolated femoral artery. J Cardiovasc Pharmacol 46 (2005) 361-368
84. Lam F.Y., Ng S.C., Cheung J.H., and Yeung J.H. Mechanisms of the vasorelaxant effect of Danshen (Salvia miltiorrhiza) in rat knee joints. J Ethnopharmacol 104 (2006) 336-344
85. Chen Y., Ruan Y., Li L., et al. Effects of Salvia miltiorrhiza extracts on rat hypoxic pulmonary hypertension, heme oxygenase-1 and nitric oxide synthase. Chin Med J 116 (2003) 757-760
86. Wang X., Pang J., Shan C., Yang S., and Zheng Y. Effect of Danshen injection on pulmonary thromboembolism and platelet free radical levels in mice. Zhongguo Zhong Yao Za Zhi 21 (1996) 558-560
87. Zhou H.K., Hong Z.L., Liu M.S., Zhang S.L., Wang Z.L., and Zheng F.H. The effect of Danshen on right ventricular function and blood rheology in chronic cor pulmonale. Chin J Integr Tradit West Med 4 (1984) 220-221
88. Guo R., Pittler M.H., and Ernst E. Herbal medicines for the treatment of COPD: a systematic review. Eur Respir J 28 (2006) 330-338
89. Wei Z.M. Effects of injection Salviae miltiorrhizae on senile chronic asthmatic bronchitis patients. Zhongguo Zhong Xi Yi Jie He Za Zhi 16 (1996) 402-404
90. Coca S.G., Krumholz H.M., Garg A.X., and Parikh C.R. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA 296 (2006) 1377-1384
91. Wojcikowski K., Johnson D.W., and Gobe G. Medicinal herbal extracts - renal friend or foe? Part two: herbal extracts with potential renal benefits. Nephrology 9 (2004) 400-405
92. Yokozawa T., Chung H.Y., Oura H., Nonaka G., and Nishioka I. Isolation of a renal function-facilitating constituent from the Oriental drug, Salviae miltiorrhizae radix. Nippon Jinzo Gakkai Shi 31 (1989) 1091-1098
93. Yokozawa T., Zhou J.J., Hattori M., et al. Effects of a Dan Shen component, magnesium lithospermate B, in nephrectomized rats. Nippon Jinzo Gakkai Shi 37 (1995) 105-111
94. Kang D.G., Oh H., Sohn E.J., et al. Lithospermic acid B isolated from Salvia miltiorrhiza ameliorates ischemia/reperfusion-induced renal injury in rats. Life Sci 75 (2004) 1801-1816
95. Lu F.M., and Lin S.Y. Effects of FDP and Danshen on renal cortical Na-K-ATPase activity in rats after treatment with renal ischemia and gentamicin. Chin Med J 102 (1989) 516-523
96. Cao Y. Clinical observation on acupoint-injection of Chinese drugs for treatment of hypertensive renal lesion. Zhongguo ZhenJiu 25 (2005) 21-23
97. Tan X.H., Xue W.J., and Ding X.M. Application of Danshen injection on early stage of renal transplantation. Zhongguo Zong Xi Yi Jie He Za Zhi 25 (2005) 404-407
98. Bao H.Y., Yu H.L., and Wang L. Study on effect of Salvia injection in treating primary nephrotic syndrome and on endothelin and serum interleukin-2 receptor in children. Zhongguo Zhong Xi Yi Jie He Za Zhi 22 (2002) 28-29
99. Friesinger II G.C., and Gavin III J.A. Diabetes and the cardiologists: a call to action. J Am Coll Cardiol 35 (2000) 1130-1133
100. Zhang M., Li X., Jiu G., and Liu Y. Effect of Danshen injection on expression of platelet membrane glycoproteins in patients with type II diabetes mellitus. Zhong Yao Cai 26 (2003) 738-740
101. Zhang M., Li X., Qin G., Liu Y., and Zhao X. Effects of Danshen injection on the reserve of tissue plasminogen activator and nitric oxide in endothelium and vasodilatation in diabetic patients. Zhong Yao Cai 28 (2005) 529-532
102. Wu H.N., and Sun H. Study on clinical therapeutic effect of composite Salvia injection matched with Western medicine in treating diabetic foot. Zhongguo Zhong Xi Yi Jie He Za Zhi 23 (2003) 727-729
103. Liu G., Guan G.J., Qi T.G., et al. Protective effects of Salvia miltiorrhiza on rats with streptozotocin diabetes and its mechanism. Zhong Xi Yi Jie He Xue Bao 3 (2005) 459-462
104. http://www.nlm.nih.gov/medlineplus/druginfo/natural/patient-danshen.html . Accessed September 24, 2006.
105. http://www.drugdigest.org/DD/DVH/HerbsTake/0,3927,553134/Danshen,00.html . Accessed September 24, 2006.
106. Cheng T.O. Herbal remedies. Am Fam Physician 60 (1999) 1661
107. Cheng T.O. Interaction of herbal medicine with coumadin. J Emerg Med 18 (2000) 122
108. Cheng T.O. Ginseng-warfarin interaction. Am Coll Cardiol Curr J Rev 9 1 (2000) 84
109. Cheng T.O. Herbal interactions with cardiac drugs. Arch Intern Med 160 (2000) 870-871
110. Cheng T.O. Another common herb that patients take but don't tell their physicians about. Consultant 44 (2004) 743
111. Cheng T.O. Herbal interactions with cardiac drugs. Cardiol Rev 22 (2005) 19-20
112. Cheng T.O. Herbal interactions with warfarin. South Med J 98 (2005) 748 [Erratum 2005;98:966]
113. Cheng T.O. Ginseng and other herbal medicines that interact with warfarin. Int J Cardiol 104 (2005) 227
114. Cheng T.O. Warfarin interaction with herbal drugs and food. Int J Cardiol 119 (2007) 107-108
115. Chan K., Lo A.C., Yeung J.H., and Woo K.S. The effects of Danshen (Salvia miltiorrhiza) on warfarin pharmacodynamics and pharmacokinetics of warfarin enantiomers in rats. J Pharm Pharmacol 47 (1995) 402-406
116. Bullington W.M., and Nappi J. Dietary supplements can interact with CV drugs. Today Cardiol 7 5 (2004) 21-22
117. Cheng T.O. Paul D. White lecture - cardiology in People's Republic of China. In: Russek H.I. (Ed). New horizons in cardiovascular practice (1975), University Park Press, Baltimore 1-27
118. Cheng T.O. Ask patients which herbal drugs they smoke as well as eat. West J Med 172 (2000) 82
119. Cheng T.O. Comment: drug-herb interaction. Ann Pharmacother 35 (2001) 124
120. Wahed A., and Dasgupta A. Positive and negative in vitro interference of Chinese medicine dan shen in serum digoxin measurement. Elimination of interference by monitoring free digoxin concentration. Am J Clin Pathol 116 (2001) 403-408
121. Dasgupta A. Clinical utility of free drug monitoring. Clin Chem Lab Med 40 (2002) 986-993
122. Datta P., and Dasgupta A. Effect of Chinese medicine Chan Su and Danshen on EMIT 2000 and Randox digoxin immunoassays: wide variations in digoxin-like immunoreactivity and magnitude of interference in digoxin measurement by different brands of the same product. Ther Drug Monit 24 (2002) 637-644
123. Chow L., Johnson M., Wells A., and Dasgupta A. Effect of the traditional Chinese medicine Chan Su, Lu-Shen-Wan, Dan Shen, and Asian ginseng on serum digoxin measurement by Tina-quant (Roche) and Synchron LX system (Beckman) digoxin immunoassays. J Clin Lab Anal 17 (2003) 22-27
124. Wahed A., Pollard J., Wells A., and Dasgupta A. Impaired protein binding of Chinese medicine Danshen in uremic sera and sera with hyperbilirubinemia: rapid assessment of total and free Danshen concentrations using the fluorescence polarization immunoassay for digoxin. J Clin Lab Anal 17 (2003) 179-183
125. Dasgupta A., and Szelei-Stevens K.A. Neutralization of free digoxin-like immunoreactive components of oriental medicines Dan Shen and Lu-Shen-Wan by the Fab fragment of antidigoxin antibody (Digibind). Am J Clin Pathol 121 (2004) 276-281
126. Gupta D., Jalali M., Wells A., and Dasgupta A. Drug-herb interactions: unexpected suppression of free Danshen concentrations by salicylate. J Clin Lab Anal 16 (2002) 290-294
127. Hu Z., Yang X., Ho P.C., et al. Herb-drug interactions: a literature review. Drugs 65 (2005) 1239-1282
128. Qiao J., Hou P., Li Y., and Abliz Z. Effects of the aqueous extract from Salvia miltiorrhiza Bge on the pharmacokinetics of diazepam and on liver microsomal cytochrome P450 enzyme activity in rats. J Pharm Pharmacol 55 (2003) 1163-1167
129. Wang A.M., Sha S.H., Lesniak W., and Schacht J. Tanshinone (Salvia miltiorrhiza extract) preparations attenuate aminoglycoside-induced free radical formation in vitro and ototoxicity in vivo. Antimicrobial Agents Chemother 47 (2003) 1836-1841
130. Vacca G., Colombo G., Brunetti G., et al. Reducing effect of Salvia miltiorrhiza extracts on alcohol intake: influence of vehicle. Phytother Res 17 (2003) 537-541
131. Colombo G., Serra S., Vacca G., et al. Identification of miltirone as active ingredient of Salvia miltiorrhiza responsible for the reducing effect of root extracts on alcohol intake in rats. Alcohol Clin Exp Res 30 (2006) 754-762
132. Xu B.J., Zheng Y.N., and Sung C.K. Natural medicines for alcoholism treatment: a review. Drug Alcohol Rev 24 (2005) 525-536
133. Cheng T.O. Panax (Ginseng) is not a panacea. Arch Intern Med 160 (2000) 3329
134. Zhang H., and Cheng Y. Solid-phase extraction and liquid chromatography-electrospray mass spectrometric analysis of saponins in a Chinese patent medicine of formulated Salvia miltiorrhizae and Panax notoginseng. J Pharm Biomed Anal 40 (2006) 429-432
135. Ng T.B. Pharmacological activity of sanchi ginseng (Panax notoginseng). J Pharm Pharmacol 58 (2006) 1007-1019
136. Ling S., Dai A., Guo Z., Yan X., and Komesaroff P.A. Effects of a Chinese herbal preparation on vascular cells in culture: mechanisms of cardiovascular protection. Clin Exp Pharmacol Physiol 32 (2005) 571-578
137. Kleiner S.M. The true nature of herbs. Phys Sportsmed 23 10 (1995) 13-14
138. Winslow L.C., and Kroll D.J. Herbs as medicines. Arch Intern Med 158 (1998) 2192-2199
139. The Pharmacopoeia Commission of PRC. Pharmacopoeia of the People's Republic of China, 2005 Edition vol. 1 (2005), Chemical Industry Press, Beijing 527-528
140. Jia H.P. Traditional medicines make delicate advance. http://www.chinadaily.com.cn/english/doc/2005-06/30/content_455808.htm Accessed September 10, 2006
141. WHO. Guidelines for the assessment of herbal medicine (1991), World Health Organization, Munich
142. Ma L.J., Zhang X.Z., Zhang H.P., and Gan Y.R. Development of a fingerprint of Salvia miltiorrhiza Bunge by high-performance liquid chromatography with a coulometric electrode array system. J Chromatogr B 846 (2007) 139-146
143. n. J Chromatogr B 846 (2007) 32-41
144. Wang X., Morris-Natschke S.L., and Lee K.H. New developments in the chemistry and biology of the bioactive constituents of tanshen. Med Res Rev 27 (2007) 133-148
145. Tang J.L. Research priorities in traditional Chinese medicine. BMJ 333 (2006) 391-394
146. Suh S.J., Jin U.H., Choi H.J., et al. Cryptotanshinone from Salvia miltiorrhiza Bunge has an inhibitory effect on TNF-alpha-induced matrix metalloproteinase-9 production and HASMC migration via down-regulated NF-kappaB and AP-1. Biochem Pharmacol 72 (2007) 1680-1689
147. Hsieh T.C., and Wu J.M. Differential control of growth, cell cycle progression, and gene expression in human estrogen receptor positive MCF-7 breast cancer cells by extracts derived from polysaccharopeptide I'm-Yunity and Danshen and their combination. Int J Oncol 29 (2006) 1215-1222
148. Huth E.J., and Murray T.J. Medicine in quotations. 2nd Ed. (2006), American College of Physicians, Philadelphia 397